Life Sciences Archive » June, 2019

Life Sciences - June, 2019

333 articles

• Ex-J&J Doc Defends Co.'s Opioid Marketing In Okla. Trial
• High Court Census Ruling Could Escalate Rule Challenges
• Insurers Lose Bid To Lift Stay In J&J Talc Supplier Ch. 11
• FCA Decision Tracker: More Interpretations Of Escobar
• Chemours Sues DuPont Over 'Lowball' Cleanup Tab
• Reed Smith Atty's Widow Wants $3M Jury Verdict Restored
• Conservative Justices Cross Over To Create Unusual Lineups
• The Sharpest Dissents Of The Supreme Court Term
• Theranos Founder Holmes Gets Aug. 2020 Criminal Trial Date
• 1st Circ. Affirms Dismissal Of Investor's Biogen Suit
• Medtronic Insulin Pumps Yanked For Possible Hacking Threat
• MoFo Snags FDA Expert From Mintz As Life Sciences Partner
• Jury Awards Ky. Seed Co. $2.4M In Trade Secrets Suit
• 2nd Circ. Questions Shkreli's Bad Jury Instruction Argument
• J&J Hit With $500K Verdict In Latest Philly Mesh Case
• Sotomayor, Breyer Vie For Chattiest High Court Justice
• Top 10 Techniques For Crafting A Dazzling Brief
• Justices Told To Skip Ex-Pfizer Exec's ERISA Venue Case
• Limited Deference Owed USPTO After High Court Kisor Ruling
• 2 Firms Score $5.6M For Work On $18.7M Chiasma Deal
• The Funniest Moments Of The Supreme Court Term
• The New 'Roberts Court' Finds Its Footing
• Ex-J&J Doc Tells Okla. Judge Its Opioids Had Low Abuse Rate
• Breaking Down The Vote: High Court Term In Review
• SEC Targets 4 Attys Over Alleged Roles In PixarBio Fraud
• Goodwin-Led BridgeBio Tops 3 Biotech IPOs Totaling $749M
• The Firms That Won Big At The Supreme Court
• Senate Panel OKs Bill Targeting Tribes' Drug Patent Buys
• J&J Gets Case Removal Extension In Talc Supplier's Ch. 11
• Ancestry.com Shared Private Health Info Of Thousands: Suit
• Indian Man Charged With Drug Smuggling, Money Laundering
• Vectura Demands Another $44M In Inhaler IP Clash
• 2 Firms Steer Bracco's $450M Diagnostic Imaging Biz Buy
• Judge Asks 3rd Circ. To Probe Pa. Device Defect Claim
• Sterigenics Floats Plan To Reopen Ill. Plant And Cut Emissions
• EU Fines Canon €28M For Skirting Toshiba Deal Reporting
• A New Court Approach To DOJ And SEC Parallel Proceedings
• J&J Can't Blame Okla. For Opioid Crisis, Official Testifies
• McKesson Dodges Generic Drug Price-Fix MDL For Now
• Bayer Taps Skadden Atty To Advise On Roundup Litigation
• Medical Device Co. Gets Access To $20M In Bankruptcy Loans
• Deals Rumor Mill: Magellan, HDFC Bank, Everest Medicines
• NJ Governor Knocks Lawmakers For Dropping Opioid Fee
• Debt Collector Sued Over Medical Provider Data Breach
• Del. Justices Deny Appeal Over Unsealing Of Chemours Suit
• Key Takeaways From USDA's Biotech Regulation Proposal
• USPTO's 'Peculiar' Fee Rule Hurts Inventors, IP Attys Say
• 2nd Of 5 NY Docs Eyed For Taking Insys Kickbacks Cops Plea
• Patent Transfers Dip Nearly A Quarter, With Tech Hardest Hit
• Private Investors Inject $104M Into Encoded Therapeutics
• A Chat With Ballard Spahr Diversity Chief Virginia Essandoh
• Opioid Deaths Will Rise Without J&J Fix, Okla. Judge Told
• USPTO Launches New Round In CRISPR Patent War
• Pharma, Tech Cos. Back Proposal To Expand Patent Eligibility
• 'Superbug' Firm Gets Ch. 11 Sale OK'd, Will Sell More Assets
• Split 9th Circ. Revives Suit Over Depositor's Ponzi Claim
• Opioid MDL Judge Seems Open To Novel Deal Approach
• Stem Cell Patients Win Cert. In 'Complex And Troubling' Suit
• Colgate False Ad Class Cert. Washes Out In 9th Circ.
• Womble Bond Nabs Privacy Partner In Boston
• Big Pharma's Biggest New Cases Of 2019: Midyear Report
• Deals Rumor Mill: Magellan, Miniso, Woodford
• Enzo's DNA Testing Patents Don't Hold Up, Fed. Circ. Affirms
• Judging A Book: McMahon Reviews 'Roosevelt For The Defense'
• Vesalius Biocapital Closes €120M Life Sciences-Focused Fund
• Invisalign Maker Tries To Ditch Suit Over Expiring Patents
• Jury Orders Express Scripts To Pay $82M In Sale Fraud Suit
• 4 Firms Guide AbbVie's $63B Bet On Allergan
• Teva Pharma Gets Nod For $85M Opioid Deal With Okla. AG
• J&J Pokes At Okla.'s $13B Plan To Fix Opioid Crisis
• Mesh Case Has Weak Ties To Pa., J&J Tells State Justices
• Genetic Testing Co. Can't Limit Damages In Privacy Suit
• $925M High Enough For ViSalus Robocall Damages: Judge
• Abiomed Asks 1st Circ. Not To Revive Exec's $5M Bonus Suit
• Akorn Disclosure-Only Deals Axed Over 'Worthless' Info
• Fed. Circ. Finds Teva Infringed UCB Parkinson's Patch Patent
• 5 Cos. Heat Up July IPO Pipeline With Filings Totaling $547M
• Cancer Center Claims Drug Cos. 'Robbed' It Of IP Revenue
• 'Negotiating Class' Bid Slammed In Opioid MDL
• Fed. Circ. Lets Merck Add Parent Co. Without Resetting IPR
• High Court Roundup: Justices Won't Hear 3 Patent Cases
• DHS Contractor Fired For Reporting Boss' Fraud, Suit Says
• Drugmakers' Emails, Calls Show Price-Fix Coverup, AGs Say
• Sacklers Can't Escape NY Opioid MDL
• Valeant Kickback Case Puts Skilling To Test In 2nd Circ.
• Bristol-Myers Will Cut Top Celgene Drug To Close $74B Deal
• New FDA Database To Aid Generic-Drug Makers' Decisions
• J&J Opioid Program For Schools A Marketing Tool, Judge Told
• Ga. Court Sides With Sperm Bank In Sham-Donor Suit
• Juul May Struggle Getting FDA Approval, Gottlieb Says
• 3rd Circ. Partly Revives Heraeus Trade Secrets Suit
• What Coons And Tillis Learned At Patent Reform Hearings
• FDA Decries Drugmaker's Promos On Facebook, 'The View'
• Biggest Health And Life Sci Rulings Of 2019: Midyear Report
• Dozen Firms Guide 9 IPOs Exceeding $2B To End June
• Va. Suits Alleging Janssen Cancer Drug 'Monopoly' Sent To NJ
• Top Product Liability Cases Of 2019: Midyear Review
• Generic Drug Cos. Still Trying To Rein In AG Disclosures
• Taxation With Representation: Wachtell, Skadden, Schulte
• Anti-Terrorism Act Case Could Bring New Risks For US Cos.
• GOP Rep. Sees Patent Eligibility Reform On The Way
• Medical Device Firm Says Sabotage Suit Should Stand
• Okla.'s Abatement Plan Takes Center Stage In J&J Opioid Trial
• Whistleblower Seeks Justices' Take On $34M FCA Award Flip
• US Trustee Flags Ch. 11 Sale Restrictions In Bid For Aegerion
• 6th Circ. Rules DEA, Drug Cos. Can't Hide Opioid Data
• Deals Rumor Mill: UnitedHealth, Fortress, Chevron Phillips
• Zimmer Biomet Hit With Chancery Suit Over $2B PE Cashout
• SEC Accuses Overseas Traders Of Manipulation Scheme
• Shkreli Settles Disputes With His Former Drug Co. Retrophin
• Billionaire's Exit From Cancer Drug Co. Gets OK In Del.
• GSK Tries To Address EU Concerns Over Pfizer Merger
• 4 Biotech Cos. Raise $476M In Cooley, Davis Polk-Led IPOs
• Opko Granted Stay On Fla. 'Pump-And-Dump' Cases
• Suspects In $27M Pump-And-Dump Seek Exit From SEC Suit
• Buyers Of Cynosure Fat-Reduction Tool Push For Class Cert.
• Contaminated Cosmetics: Recalls, Lawsuits And Legislation
• J&J Exec Defends Group Okla. Witness Called 'Opioid Mafia'
• McKesson Lands Seat On Insys Creditors Committee
• Keryx Fights Investor's Bid To Lead Kidney Drug Stock Suit
• AbbVie, Investors Reach $17M Deal Over Failed Inversion
• Fed. Circ. 'Garbled' Halo Ruling, Zimmer Tells High Court
• 3rd Circ. Won't Revive Ex-Medco Exec's FCA Kickback Suit
• J&J Can't Blame Colgate, Avon In Talc Punitive Damages Trial
• San Francisco Poised To Ban Sales Of E-Cigarettes
• Clovis Directors Plead Ignorance On Rules In Drug Trial Suit
• Fenwick-Led Stoke Therapeutics Prices Upsized $142M IPO
• PTAB Says ITC Case Doesn't Bar Dental Patent Challenge
• Amphastar To Get $60M In Settlement With Rivals
• TridentUSA Ch. 11 Plan Slammed For Risking 'Repeat Failure'
• Fla. Jury Awards $70M Verdict To Couple In Asbestos Suit
• Okla. Opioid Deaths Have Familiar Face, J&J Trial Judge Hears
• Doc's Dropped Defect Defense Sank Med Mal Case, Panel Told
• Dems Question HHS Patent Enforcement, Citing Truvada Woes
• Swift Ruling Vowed On Rule Requiring Drug Prices In TV Ads
• Monsanto Looks To Whack $2B Roundup Verdict
• Judge Urged To Ax Lead Pa. Opioid Marketing Deception Case
• Debt Collection Co. Files Ch. 11 After Health Data Breach
• Was A $5M Fine Just The Cost Of Closing A $6B Deal?
• Sequenom Scores Patent Win Against Ariosa In The UK
• Deals Rumor Mill: Dish, Chi-Med, NiSource
• Asacol Buyers Say Product-Hopping Suit Requires Trial
• J&J Must Face Fast-Tracked Talc Trial On Punitive Damages
• UK Says Illumina's $1B Genomic Sequencing Deal Problematic
• Kramer Levin Lands Ex-Patterson Belknap IP Partner In NY
• A Guide To FCA Cooperation Credit For Life Sciences Cos.
• Bernstein Litowitz Seeks $11M In Fees For $45M Waste Deal
• USTR Pledges Close Work With Congress To Pass NAFTA 2.0
• The Biggest Insurance Decisions Of 2019: Midyear Report
• J&J Asks Okla. Judge To Strike 'Partisan' Opioid Expert
• Fed. Circ.'s Vimovo Ruling Harms Innovation, Horizon Says
• FCC Robocall Waiver Could Affect High-Stakes ViSalus Suit
• Allergan Hid Breast Implants' Cancer Risks, Suit Says
• In The Trade Hot Seat: What Congress May Ask Lighthizer
• Calif. Man Says Monsanto Can't Ditch $80M Roundup Award
• Mylan Escapes Novartis MS Drug Patent Suit
• Insys Hit With Nationwide Opioid Class Claim In Ch. 11
• How Purdue Opioid Win Could Bolster J&J In Okla. Trial
• Online Luxury Reseller Leads 5 IPO Launches Totaling $936M
• 5 Ways Law Firms Can Improve Their Job Interviews
• High Court Won't Review Block On ACA Birth Control Rules
• Wachtell, Skadden Shape $11.4B Pfizer-Array Deal
• Slack's Direct Listing, Robust IPO Lineup To Heat Up June
• Amazon's Arbitration Pact In 'Place Your Order' Link Holds Up
• Feds Can't Pause SEC's Civil Suit Against Ex-Theranos Exec
• 3 Takeaways As 'Negotiation Class' Idea Jolts Opioid MDL
• J&J Presses Expert On 'Opioid Mafia' Claim In Okla. Trial
• GSK Calls $90M Inhaler IP Damages 'Wildly Inflated'
• New Bill Would Reshape Drug Patent Cases In Uncertain Ways
• Patient Attys Slam 3M's Contempt Bid Over Unsealed Docs
• Insurer Fights $19M Atty Fee Bid In Heparin Coverage Suit
• Pharma Cos. Sue HHS Over Putting Drug Prices In Ads
• Troutman Sanders Lures IP Litigator From Mintz
• Chancery Keeps Alive Suit Over Repriced Anixa Stock Options
• 2 Firms Guide $825M In Health Care Data, Biopharma IPOs
• Horizon's Arthritis Drug Patent Under Scrutiny At PTAB
• Taxation With Representation: Skadden, Wachtell, Fenwick
• State Efforts To Rein In Drug Costs Have Mixed Success
• A Rare Antitrust Deferred Prosecution Agreement From DOJ
• Endo Fights Investor's Cert. Bid In Opioid Stock-Drop Suit
• Recreational Marijuana Legislation Is At A Standstill In NY
• Health Hires: Lathrop Gage, Goodwin, Shockwave Medical
• 'Negotiation Class' May Tee Up Sweeping Deal In Opioid MDL
• State Sovereign Immunity Doesn't Apply In IPRs: Fed. Circ.
• Okla. Opioid Expert Is Motivated By Money, J&J Tells Judge
• Man Charged With $4.7M Sanofi Insider Trading Scheme
• FDA Puts Forth 10-Month Deadline For E-Cig Applications
• Chamber, Drugmakers Back AbbVie In $448M FTC Fine Appeal
• 9th Circ. Breathes New Life Into CVS Drug Pricing Suit
• Ex-Theranos Execs' Bid For Docs Is Unreasonable, Feds Say
• IP Boutique Desmarais Expands To West Coast With SF Office
• J&J Loses Bid To Keep Talc Cancer Case Out Of Philly
• How To Streamline Virtual Law Team Mass Tort Defense
• Saving Seaweed Via Maine Property Law
• J&J Pushed Opioids Like Drug Dealer, Doctor Tells Trial Judge
• Feds Roasted On Proof In CEO's $3M Bank Fraud Conviction
• 4th Circ. Says Mail-Order Pharmacy Must Face Death Suit
• Medtronic Can't Escape Male Ex-Worker's Gender Bias Suit
• New Bill Would Make It Easier To Invalidate Drug Patents
• FDA Offers 'Rapid' Help As Stem Cell Approval Deadline Nears
• Shoshone Tribe Joins Opioid MDL, Details Epidemic's Impact
• Insurer Seeks Revival Of RICO Suit In Testosterone MDL
• NJ, Texas Firms Unlawfully Pocketed Mesh Funds, Suit Says
• Fed. Circ. Won't Revive Colitis Patent Axed By PTAB
• Biotech Co. Illumina Inks $14M Deal To End Stock-Drop Suit
• The SEC Is Cracking Down On Insider Trading By Lawyers
• FDA Flouted Law To Undercut $375K Drug, Suit Says
• Why I Became A Lawyer: A Fateful Phone Call
• Insuring The Ever-Growing Cannabis Industry: Part 2
• Calif. Jury Awards $12M In Talc Suit Against J&J, Colgate
• Wellness Co. CEO Pleads Guilty To Penny Stock Fraud
• Skadden, Norton Rose Guide Dassault's $5.8B Medidata Buy
• Law Firms Can Do Better With Their Mentoring Programs
• Confidentiality: The New Employee Arbitration Battleground
• J&J's Sales Plan Caused Opioid Addiction, Okla. Judge Hears
• Refined Patent Eligibility Bill Coming This Summer, Sens. Say
• U Of Minn. Says High Court Helped Case For PTAB Immunity
• PTAB Invalidates Vibrating Orthodontic Device Patent
• Wound Care Co. Pays $15M, Admits Contamination Cover-Up
• EPA Glyphosate Findings Key In Monsanto Verdict Challenges
• TridentUSA, Silver Point Seek End To Refinancing Challenge
• New HHS Inspector General 'Not Afraid To Do Anything'
• Insys Seeks Speedy Ch. 11 Sale As Liabilities Mount
• J&J Unit Seeks Kirkland's Pfizer Docs In Antitrust Fight
• Med. Device Co.'s Inflated IPO Hurt Shareholders, Suit Says
• Teva's $85M Opioid Settlement Denied Court Approval
• GSK Seeks Ax Of Zofran Birth Defect Claims
• USTR Flooded With Pleas To Resist New Tariffs On China
• BakerHostetler Lands Ex-PwC Principal To Head Int'l Tax Team
• IP's Developing Role In Cannabis Business Strategy
• Lack Of Proof Dooms Bayer Contraceptive MDL, Judge Says
• FTC Wants More Info On $4.8B Roche Buy Of Swiss Gene Co.
• Okla. Needs $295M To Undo J&J Opioid Marketing, Judge Told
• Vitamin Shoppe Sells Toxic Male Supplement, Consumer Says
• Toshiba, Canon To Pay $5M For Merger Clearance Violation
• Express Scripts Leans On BCBS Ruling In 2nd Circ. Battle
• BioScrip Investor Wants More Details On Option Care Merger
• Acadia Tries To Nix Investor Suit Over Drug Deaths
• PE-Backed Grocer Leads 5 IPO Launches Totaling $700M
• The Latest Developments In Criminal Cases Against Execs
• 'Rocket Docket' Justifies Its Name For 11th Straight Year
• The 'Newly Acquired Information' Shift In Pharma Litigation
• Thermo Fisher Drops $925M Gatan Deal Under UK Pressure
• DOJ Can't Use 'Minimal' Probe To End FCA Suit, Judge Says
• Why Bellwethers Matter In The Opioid MDL
• Merck Buys Again, Adding Biopharma Tilos In $773M Deal
• Insys Hits Ch. 11 After $225M Kickback Settlement
• Does Multidistrict Litigation Deny Plaintiffs Due Process?
• Opioid Addict Hooked From First Pill, Judge In J&J Trial Hears
• Novartis Attacks $3M Atty Fees Bid In Whistleblower Case
• Pa. County, For Now, Drops Bid To Blow Up Opioid Mass Tort
• 'Legal Impossibility' Lets Convicted Ex-NECC Execs Off Hook
• InvaGen Agrees To Admit Infringing Diabetes Drug To End Suit
• UK Litigation Roundup: Here's What You Missed In London
• Drug Cos. Hit Back In High Court 'Blocking Patent' Fight
• Meet The Top Attys In AbbVie's Antitrust Battle Royal
• Janssen OK With Combining Zytiga Suits If They're Sent To NJ
• Tribe Must Wait On USDA Rules To Grow Hemp
• J&J Talc Case Can Go Ahead In Fla. While Move To Del. Mulled
• GSK Consultants' Suit Over Prison Stint Returns To Pa. Court
• Deals Rumor Mill: Sibur, Caesars, Toro Gold
• States Call For Unredacting Of Their Generic-Drug Pricing Suit
• Fake CBD Drink Sent Co.'s Stock Skyrocketing, Suit Says
• Insys Pleads Guilty To Fraud In Opioid Bribe Scheme
• Issues To Watch In Fed. Circ. Hep C Drug Patent Case
• When Experts Are Effective In Insurance Coverage Litigation
• Combating False Celebrity Endorsements Online
• J&J Profited From Opioid Misinformation 'Virus,' Doc Says
• Chinese Co. Infringed Cholesterol Test Patents: ITC Judge
• Trade Groups Back Senate Plan To Fight Surprise Medical Bills
• AbbVie Development Partner Hits Back At $31M FTC Penalty
• Ex-Shire Unit Exec Reaches $2.5M Deal In Kickback Case
• Takeda Bid To DQ Baker Botts 'Spurious At Best,' Judge Says
• Third Rock Raises $770M To Boost Biotech Portfolio
• 3M Moves For Contempt, Says Patient Attys Used Sealed Docs
• Lilly Urges High Court To Review Its $20M Cialis Patent Loss
• J&J Asbestos Suit Sent Back To Mass. State Court
• Feds Argue Wire Fraud Needs No Insider Trading Tweaks
• Perrigo Set Up Israeli Co. To Skip Tax, US Says In $163M Row
• Measuring The Value Of A Law Firm's Social Media Efforts
• Insys Chairman To Resign In Wake Of $225M Deal With Feds
• Senate Scrutinizes Patent Bill's Effect On Drug Prices, Genes
• J&J Targets Pain Doc's Testimony In Okla. Opioid Trial
• PTAB Struggles To Parse Arguments In Acne Drug Patent Suit
• FDA, Indivior Say Braeburn Fibbing In Opioid Exclusivity Suit
• Insys To Pay $225M To End DOJ's Opioid Scheme Probe
• Mallinckrodt Used Charity As Kickback Conduit, Feds Say
• Calif. Clinic's Parent Co. Urges Toss Of Destroyed Embryo Suit
• WashU Urges 3rd Circ. To OK WARF's $32M Royalties Loss
• Calif., NY Supplement Buyers Win Cert. Of False-Ad Suit
• Court OKs Cancer Center's Revised $7.2M Antitrust Deal
• Pa. Medical Pot Cos. Can Shield Security Info From Media
• Kalobios Successor Sued Over Drug Development Deal
• Ex-Health Co. Execs Want Out Of Roche Test Strip Fraud Suit
• Pharma Co. Hid Value To Shrink Payout, Says Former Exec
• Ex-AbbVie Counsel Rejoins Ice Miller In Benefits Practice
• A Cautionary Word For Providers Of Drug Addiction Treatment
• Holland & Knight Nabs Ballard Spahr M&A Atty In Philly
• Calif. Inks Settlement With Endo Over Pay-For-Delay Scheme
• Bill To Broaden Patent Eligibility Spurs Clash At Sen. Hearing
• J&J Tells Okla. Judge It Obeyed FDA When Selling Fentanyl
• Ex-HHS Watchdog Says Anti-Fraud Revamp Going Too Slowly
• Forest Labs Scorched By 'Displeased' Judge After Fire Drill
• SG Deviated From Set Patent Law, Ariosa Warns Justices
• King & Spalding Atty Faces Sanctions Bid As Talc Trial Wraps
• Feds Win Bid To Stop Unapproved Stem Cell Treatment
• Hearing Aid Co. Workers Say Ex-Execs' Fraud Hurt Stock Plan
• Pomerantz To Lead Lexicon Pharmaceuticals Securities Suit
• Reports On USMCA Offer Industry-Specific Guidance For Cos.
• A First Look At The New Illinois Cannabis Legislation
• Illumina Hit With Derivative Suit Over $6.6B Stock Drop
• Pfizer Wins NJ High Court Review Of Forced-Arbitration Ruling
• 44 States' Generic-Drug Pricing Suit Rolled Into Pa. MDL
• What We Learned From FDA's Public Hearing On Cannabis
• Despite Amarin, ITC May Be Right Prescription For Pharma
• Drugmakers Want AGs' Generics Price-Fixing Claims Tossed
• Monsanto Looks To Nix $80M Loss In 1st Fed. Roundup Trial
• J&J Wanted To Overcome 'Opiophobia,' Okla. Judge Hears
• J&J, Colgate Created 'Severe Health Hazard,' Talc Jury Told
• Rosen Law Snags Lead Counsel In Pharma Stock-Drop Suit
• Meet The Judge Overseeing The First Opioid Trial
• PTAB Takes Up Dr. Reddy's Suboxone Patent Challenge
• Semenya Gets Nod To Compete During Testosterone Appeal
• DC, More States Sue Purdue, Sacklers Over Opioid Crisis
• Health Cos. Renew Becton Price-Fix Claim After Apple Case
• Barrett & Singal Creates New 'Research Misconduct' Practice
• Weitz & Luxenberg Urges 2nd Circ. To Toss Fraud Suit
• Hospital Must Face Suit For Using Recalled Medtronic Device
• Proposed Classes Ask To Combine Janssen Antitrust Suits
• Supreme Court Refuses 'Blocking Patent' Rule Case
• Deals Rumor Mill: Bayer, Thomas Cook, KKR
• J&J Unit Urges ITC To Investigate Intuitive Surgical's Imports
• Draft Patent Eligibility Bill Is On The Right Track